Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries

Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH)

(2022) Francis H. Glorieux et al.   Orphanet Journal of Rare Diseases

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia

(2022) Leanne M Ward et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical practice guidelines for paediatric X‐linked hypophosphataemia in the era of burosumab

(2022) Jessica L Sandy et al.   JOURNAL OF PAEDIATRICS AND CHILD HEALTH

Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets

(2022) Neil J. Paloian et al.   PEDIATRIC NEPHROLOGY

Diagnosis and management of X-linked hypophosphatemia in children and adolescent in the Gulf Cooperation Council countries

(2021) Fahad Al Juraibah et al.   Archives of Osteoporosis

X-linked hypophosphatemia and burosumab: practical clinical points from the French experience

(2021) Justine Bacchetta et al.   JOINT BONE SPINE

Magnetic resonance imaging is a valuable tool to evaluate the therapeutic efficacy of burosumab in children with X-linked hypophosphatemia

(2021) Volha V Zhukouskaya et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia

(2021) Agnès Linglart et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Approach to patients with hypophosphataemia

(2020) Pablo Florenzano et al.   Lancet Diabetes & Endocrinology

Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study

(2020) S. H. Lo et al.   QUALITY OF LIFE RESEARCH

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children

(2020) Aaron Schindeler et al.   Frontiers in Endocrinology

Pulp chamber features, prevalence of abscesses, disease severity, and PHEX mutation in X-linked hypophosphatemic rickets

(2020) Giampiero I. Baroncelli et al.   JOURNAL OF BONE AND MINERAL METABOLISM

A Cross‐Sectional Magnetic Resonance Imaging Study of Factors Influencing Growth Plate Closure in Adolescents and Young Adults

(2020) Ola F T Kvist et al.   ACTA PAEDIATRICA

Disease-specific gait deviations in pediatric patients with X-linked hypophosphatemia

(2020) Gabriel T. Mindler et al.   GAIT & POSTURE

Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British Paediatric and Adolescent Bone Group recommendations

(2020) Raja Padidela et al.   Endocrine Connections

Delphi Technique in Health Sciences: A Map

(2020) Marlen Niederberger et al.   Frontiers in Public Health

Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial

(2019) Michael P Whyte et al.   Lancet Diabetes & Endocrinology

FGF23 and its role in X-linked hypophosphatemia-related morbidity

(2019) Signe Sparre Beck-Nielsen et al.   Orphanet Journal of Rare Diseases

Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society

(2019) Paul Lips et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Status of growth plates can be monitored by MRI

(2019) Hiroaki Wada et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial

(2019) Erik A Imel et al.   LANCET

Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia

(2019) Dieter Haffner et al.   Nature Reviews Nephrology

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

(2019) Anthony A. Portale et al.   CALCIFIED TISSUE INTERNATIONAL

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial

(2019) Karl L Insogna et al.   JOURNAL OF BONE AND MINERAL RESEARCH

CLSI-based transference and verification of CALIPER pediatric reference intervals for 29 Ortho VITROS 5600 chemistry assays

(2018) Victoria Higgins et al.   CLINICAL BIOCHEMISTRY

Validation of a Novel Scoring System for Changes in Skeletal Manifestations of Hypophosphatasia in Newborns, Infants, and Children: The Radiographic Global Impression of Change Scale

(2018) Michael P Whyte et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Burosumab Therapy in Children with X-Linked Hypophosphatemia

(2018) Thomas O. Carpenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Magnetic Resonance Imaging Features as Surrogate Markers of X-Linked Hypophosphatemic Rickets Activity

(2017) Marta Lempicki et al.   Hormone Research in Paediatrics

Effective method for drug injection into subcutaneous tissue

(2017) Hyejeong Kim et al.   Scientific Reports

Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications

(2015) Silje Rafaelsen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Therapeutic management of hypophosphatemic rickets from infancy to adulthood

(2014) Agnès Linglart et al.   Endocrine Connections

A clinician's guide to X-linked hypophosphatemia

(2011) Thomas O Carpenter et al.   JOURNAL OF BONE AND MINERAL RESEARCH